more online @ www.accc-cancer.org

Immuno-Oncology Survey

SURVEY This new area of cancer research and treatment looks to harness the body's own immune system to fight cancer. Let us know what you want to learn about immuno-oncology and how ACCC can assist your program with implementation of immuno-oncology by taking our short survey: www.survey monkey.com/s/ICLIO_ACCC.



ACCC's 2015 Capitol Hill Day

SPEAK UP Speak up for access to quality care during visits with your Congressional representatives on Monday, March 16, 2015, and discover how much stronger the cancer care community is when we come together to advocate for our common goals. Register and learn more at: www.accc-cancer.org/CANCERSCAPE.



INFO Did you miss ACCC's call on the 2015 final rules? Log onto mynetwork@accc-cancer.org and go to the Members Resource Library to hear everything you missed.

Immunotherapy Education Series HOST ACCC seeks host centers for 60-minute, live teleconfer

ences and webcasts on "Principles and Application in Immunotherapy of Cancer." Learn the core principles of immunotherapy and review issues related to the clinical application of these therapies in specific tumor types—melanoma or lung cancer. Interested in this opportunity? Email resources@accc-cancer.org and include "PAIC" in the subject line, along with the name and contact information for your cancer program.

Oncology Issues is published bimonthly at the Association of Community Cancer Centers, 11600 Nebel St., Suite 201, Rockville, MD 20852. Copyright ©2015. Association of Community Cancer Centers. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means without permission in writing. Editorial correspondence, changes of address, manuscripts, and letters to the editor should be addressed to: Managing Editor, Oncology Issues, 11600 Nebel St., Suite 201, Rockville, MD 20852-2557. Author's instructions available at www.accc-cancer.org.

Articles, editorials, letters to the editor, and other contributed materials represent the opinions of the authors and do not represent the opinions of the Association of Community Cancer Centers or the institution with which the author is affiliated unless the contrary is specified.

Basic rate: \$55 per year for healthcare providers, plus \$4.99 for shipping. ACCC membership dues pay for general, delegate, and chapter member subscriptions. Back issues available for \$12.50 per copy, prepaid. Bulk rates available upon request.

Send correspondence, display advertising, insertion orders, printing materials to Mal Milburn, Oncology Issues, 11600 Nebel St., Suite 201, Rockville, MD 20852. Questions for general information may be directed to 301-984-5704.

Please send address changes to Association of Community Cancer Centers, 11600 Nebel St., Suite 201, Rockville, MD 20852.

For permission to photocopy or use material electronically from Oncology Issues, ISSN#1046-3356, please access www.copyright.com or contact the Copyright Clearance Center, Inc. (CCC) 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users.

"Doc Fix" Medicare Legislation Could Cost \$144 Billion Over 10 Years

-**AS**]



Source. CBO. Medicare's Payments to Physicians: the Budgetary Effects of Alternative Policies. www.cbo.gov/sites/default/files/cbofiles/attachments/49770-SGR-Menu.pdf.

Want to Avoid a RAC Audit? Try These Tips

- Avoid copy-and-paste documentation—While it is acceptable to use templates, your documentation must be patient-specific.
- Benchmark your E&M coding against your peers—AAPC offers national E&M coding averages by specialty: www.aapcps.com/ resources/em_utilization.aspx.
- Focus on medical decision making—Do not use a higher-level code when the complexity is not there, regardless of your documentation.
- 4. Four eyes are better than two—Have a certified professional coder review several chart notes for every provider, every year, for appropriate coding and documentation.
- Document medical necessity—When ordering a test or procedure, make sure you document why it is needed.

Source. Roberts LW. Six Ways to Avoid a RAC Audit. Physicians Practice. www.physcianspractice.com.



facts

What's Behind the Rapid Growth in the 340B Program?

A whitepaper identifies four historical drivers of substantial growth in the 340B Program that will continue to underpin future expansion during the next five years:

- Increase in 340B enrolled disproportionate share hospitals (DSH). Newly-enrolled DSH hospitals account for about half of total 340B drug spending in 2013. DSH hospitals purchase the vast majority more than 80%—of 340B drugs.
- Acquisition of satellite clinics by DSH hospitals. Between 2009 and 2012 these hospitals have acquired at least 140 community oncology practices; an almost 120 percent increase in 340B oncology drug utilization followed these acquisitions.
- Contract pharmacy arrangement expansion. Almost two-thirds of all 340B DSH hospitals have at least
 5 contract pharmacies; many have more than 50.
- 4. Impact of the Affordable Care Act. The ACA established new eligibility categories in the 340B Program for pediatric hospitals, critical access hospitals, sole community hospitals, rural referral centers, and freestanding cancer centers. To date, more than 1,100 of these entities have enrolled in the 340B program.

Source. Vandervelde A. Growth of the 340B Program: Past Trends, Future Projects. www.thinkbrg.com/media/publication/524_ Vandervelde_340B_GrowthDrivers_WhitePaper_20141202_FINAL.pdf.





Uninsured Americans Decline by 10.6 Million

The number of uninsured non-elderly adults fell an estimated **10.6** million between Sept. 2013-Sept. 2014 as the un-insured rate fell from **17.7%** to **12.4%**. Most of the gain in coverage was among low- and middle-income adults specifically targeted by the ACA.

Source. Long SK, et al. Taking stock: health insurance coverage under the ACA as of September 2014. *Health Reform Monitoring Service*. http://hrms.urban.org/briefs/Health-Insurance-Coverage-under-the-ACA-as-of-September-2014.html.





Biosimilar Drugs Could Create \$44 Billion in Savings in 10 Years

Source. The RAND Corporation. "The Cost Savings Potential of Biosimilar Drugs in the U.S." www.rand.org/pubs/perspectives/PE127.html.